Neuroendocrine tumors. Biotherapy.
This review gives an introduction to the classification and staging of neuroendocrine tumors, as the prognostic implications of these classifications influence therapeutic decisions. The indications for biotherapy are given, together with a short update on the mechanism of somatostatin analogs and interferon-alpha therapy. This is followed by an in-depth description of the use of biotherapy, its results with respect to symptomatic and antiproliferative treatment, as well as its side-effects.
Plöckinger
U
U
Interdisziplinäres Stoffwechsel-Centrum, Med. Klinik m. S. Hepatologie und Gastroenterologie, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany. ursula.ploeckinger@charite.de
Wiedenmann
B
B
D000172:Acromegaly / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001691:Biological Therapy / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000628:therapy*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013004:Somatostatin; D007372:Interferons